# CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients

> **NCT03591380** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 3 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Belimumab

## Key facts

- **NCT ID:** NCT03591380
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-14
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Recruitment complications due to COVID-19
- **Last updated:** 2023-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591380, "CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03591380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*